NO20085285L - 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse - Google Patents

2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse

Info

Publication number
NO20085285L
NO20085285L NO20085285A NO20085285A NO20085285L NO 20085285 L NO20085285 L NO 20085285L NO 20085285 A NO20085285 A NO 20085285A NO 20085285 A NO20085285 A NO 20085285A NO 20085285 L NO20085285 L NO 20085285L
Authority
NO
Norway
Prior art keywords
benzazepines
alkoxy
preparation
hydroxyalkylamide
well
Prior art date
Application number
NO20085285A
Other languages
English (en)
Inventor
Jidong Zhang
Alain Commercon
Frederico Nardi
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20085285L publication Critical patent/NO20085285L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Abstract

Det beskrives spesielt 2-alkoksy-3,4,5-trihydroksy-alkylamid-benzazepiner. Videre beskrives deres fremstilling, preparater inneholdende forbindelsene, anvendelsen av forbindelsene som medikamenter og særlig som antikansermedikamenter.
NO20085285A 2006-05-24 2008-12-17 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse NO20085285L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0604733A FR2901554B1 (fr) 2006-05-24 2006-05-24 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
PCT/FR2007/000866 WO2007135293A2 (fr) 2006-05-24 2007-05-23 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur préparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
NO20085285L true NO20085285L (no) 2008-12-17

Family

ID=37487536

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085285A NO20085285L (no) 2006-05-24 2008-12-17 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse

Country Status (24)

Country Link
US (1) US7994162B2 (no)
EP (1) EP2035387A2 (no)
JP (1) JP2009537614A (no)
KR (1) KR20090010071A (no)
CN (1) CN101454290A (no)
AR (1) AR061103A1 (no)
AU (1) AU2007253196A1 (no)
BR (1) BRPI0712925A2 (no)
CA (1) CA2649336A1 (no)
CR (1) CR10382A (no)
DO (1) DOP2007000104A (no)
EA (1) EA200870565A1 (no)
EC (1) ECSP088893A (no)
FR (1) FR2901554B1 (no)
GT (1) GT200800249A (no)
IL (2) IL194972A0 (no)
MA (1) MA30561B1 (no)
MX (1) MX2008014844A (no)
NO (1) NO20085285L (no)
PE (1) PE20080705A1 (no)
TN (1) TNSN08402A1 (no)
TW (1) TW200812971A (no)
UY (1) UY30368A1 (no)
WO (1) WO2007135293A2 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
CN102924462B (zh) * 2012-10-24 2015-01-14 华东师范大学 1,2,3,4,5,9-取代苯并吖庚因类化合物的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
CO5140099A1 (es) 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
US6239127B1 (en) 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
BR0110641A (pt) * 2000-05-11 2003-03-18 Novartis Ag Determinados carbonatos e éteres caprolactâmicos substituìdos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de tumores
WO2002039990A2 (en) 2000-11-14 2002-05-23 Novartis Ag Method for screening anti-proliferative compounds and inhibiting tumor growth
US6545148B2 (en) 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
JP2006528611A (ja) * 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
GT200800249A (es) 2009-05-15
CN101454290A (zh) 2009-06-10
DOP2007000104A (es) 2007-11-15
IL194972A0 (en) 2009-08-03
UY30368A1 (es) 2008-01-02
WO2007135293A2 (fr) 2007-11-29
ECSP088893A (es) 2008-12-30
AU2007253196A1 (en) 2007-11-29
PE20080705A1 (es) 2008-07-30
KR20090010071A (ko) 2009-01-28
US7994162B2 (en) 2011-08-09
EA200870565A1 (ru) 2009-06-30
TW200812971A (en) 2008-03-16
BRPI0712925A2 (pt) 2013-01-08
IL195148A0 (en) 2009-09-22
JP2009537614A (ja) 2009-10-29
MA30561B1 (fr) 2009-07-01
CR10382A (es) 2009-02-26
FR2901554A1 (fr) 2007-11-30
CA2649336A1 (fr) 2007-11-29
EP2035387A2 (fr) 2009-03-18
AR061103A1 (es) 2008-08-06
MX2008014844A (es) 2009-02-17
TNSN08402A1 (en) 2010-04-14
WO2007135293A3 (fr) 2008-05-02
US20090099152A1 (en) 2009-04-16
FR2901554B1 (fr) 2011-04-01

Similar Documents

Publication Publication Date Title
NO20090295L (no) Substituerte heteroarylderivater
SE0301700D0 (sv) Novel compounds
NO20091299L (no) Substituerte sulfonamidderivater
TW200800999A (en) Novel compounds
NO20075918L (no) Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
TW200745114A (en) Novel compounds
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
NO20082269L (no) Nye piperaziner som antimalariamidler
NO20090294L (no) Spirocykliske azaindolderivater
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
NO20081160L (no) Benzimidazoltiofen forbindelser
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
TW200639156A (en) New compounds
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
NO20064783L (no) Opplosningstabeletter med licarbazepin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application